Healthcare Industry News: HSMN NewsFeed
News Release - September 22, 2011
Cambridge Heart Announces Agreement to Distribute Its HearTwave II System in SingaporeTEWKSBURY, Mass.--(Healthcare Sales & Marketing Network)-- Cambridge Heart, Inc. (OTCBB:CAMH.ob ), a developer of non-invasive diagnostic tests for cardiac disease, today announced that it has executed an exclusive agreement with EO Medical Pte Ltd to distribute its HearTwave II System and proprietary Microvolt T-Wave Alternans™ (MTWA) software and Micro-V Alternans Sensors in Singapore upon regulatory approval.
EO Medical is a leading supplier of cutting-edge and innovative medical devices to healthcare providers. This addition is in-line with the Company’s strategy of partnering with companies that have established distribution networks, to make its technology readily available in cardiology and internal medicine physician practices and in hospitals.
“This is a great opportunity for the Company that will incrementally add to our global presence,” said Ali Haghighi-Mood, Cambridge Heart CEO. Mr. Haghighi-Mood added, “We look forward to gaining regulatory approval in Singapore, which we expect will occur within the next six to nine months, and begin marketing our MTWA technology.”
Sudden Cardiac Arrest (SCA) is the leading cause of death in the U.S. accounting for an estimated 300,000 deaths each year - more than lung cancer, breast cancer and HIV/AIDS combined. Out-of-hospital survival is less than 8 percent, making prediction and prevention critically important. It is estimated that there are approximately 10 to 12 million heart attack and heart failure patients in the U.S. who can benefit from annual MTWA testing. Microvolt T-Wave Alternans is a marker of SCA risk which is measured during a non-invasive treadmill test using Cambridge Heart's proprietary technologies. The Company's MTWA test is the only one of its kind that is reimbursed by Medicare under a National Coverage Policy.
About Cambridge Heart, Inc.
Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company’s products incorporate proprietary Microvolt T-Wave Alternans measurement technologies, including the patented Analytic Spectral Method® and ultrasensitive disposable electrode sensors. The Company’s MTWA test, originally based on research conducted at the Massachusetts Institute of Technology, is reimbursed by Medicare under its National Coverage Policy.
Cambridge Heart, founded in 1990, is based in Tewksbury, MA. It is traded on the Over-The-Counter Bulletin Board (OTCBB) under the symbol CAMH.OB.
Statements contained in this press release that are not purely historical are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as “believes”, “expects”, “anticipates”, “plans”, “estimates”, “could”, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences are identified in our most recent Annual Report on Form 10-K under “Risk Factors”, which is on file with the SEC and available at www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.
Source: Cambridge Heart
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.